Introduction
Some degenerative diseases are caused by the loss of tissue-specific cells in organs, examples include: (i) type I diabetes, in which insulin-producing b cells are destroyed by an autoimmune disorder; (ii) Parkinson's disease, in which dopamine-producing neuronal cells are destroyed; (iii) heart failure, which is caused by the massive loss of cardiomyocytes; and (iv) ischemic diseases, which is primarily caused by endothelial dysfunction. Cellular therapies to treat these diseases are hampered by the lack of donor cells. Therefore, the successful derivation of human embryonic stem cells (hESCs) 1 could provide an unlimited source of cells to replace damaged or degenerated cells and tissues caused by these diseases.
The endothelium is the first tissue to differentiate during vertebrate embryogenesis. Based on the close relationship of the vascular and hematopoietic systems during organogenesis, it was hypothesized that hematopoietic and endothelial cells are derived from a common precursor, the hemangioblast. [2] [3] [4] Commitment to the hematopoietic and endothelial lineages within the yolk sac at mouse embryonic day (E) 7.5 results in the development of blood islands that consist of an outer layer of endothelial cells and an inner cluster of primitive hematopoietic cells. Endothelial and hematopoietic cells in blood islands are derived from aggregates of hemangioblasts. [5] [6] [7] The structure of the yolk sac blood islands in the human embryo is similar to those in the mouse embryo. 8, 9 The aorta-gonad-mesonephros region of the embryo proper also contains hemogenic endothelial cells (or called angio-hematopoietic progenitors), which give rise to hematopoietic stem cells and vascular endothelial cells. [10] [11] [12] Even both of them give rise to hematopoietic and endothelial cells, it is unclear whether hemangioblasts are the same as hemogenic endothelial cells. For easy to discuss, we will use the term hemangioblast for both of them.
In the embryo proper, primitive vascular networks are formed de novo by the aggregation of embryonic endothelial cells, a process termed vasculogenesis. In addition to originating from hemangioblasts, embryonic endothelial cells arise from restricted progenitor cells, called angioblasts that are derived from the mesoderm and are committed to the endothelial lineage. 13, 14 The initial vascular network, which consists of endothelial cells that form interconnected vessels, undergoes a succession of morphogenetic events involving sprouting, proliferation and migration of endothelial cells, and remodeling to generate large branched vessels, a process called angiogenesis. Mural cells, including pericytes and vascular smooth muscle cells (SMCs) are recruited to the newly formed vessels, causing the vascular networks to be mature and become stable. 7, 15 Controlling vascular cells and angiogenesis, either positively or negatively, could be critical for the treatment of various diseases, including cardiovascular diseases and cancers.
Vasculogenesis and angiogenesis are largely dependent on the functional changes of proliferation, differentiation and migration of endothelial cells, and current angiogenesis research relies primarily on mouse models. Based on mouse models, the three families of receptor tyrosine kinases and their ligands found are: (i) vascular endothelial growth factor receptors (VEGFRs) and VEGFs; (ii) Tie receptors and angiopoietins; and (iii) Eph receptors and ephrins, which play major roles in regulating vascular development. 15 Members of the fibroblast growth factor (FGF) family and the bone morphogenetic protein (BMP) family influence mesodermal lineage specification, therefore possibly facilitating vasculature formation.
Because of ethical obstacles, the study of early vascular development in humans is hampered by the lack of experimental systems. Human umbilical vein endothelial cells are often used to study human endothelial cells. However, the signals and signaling pathways, which regulate embryonic endothelial cell fate and control endothelial cell migration and assembly into new vessels during embryonic development, remain unknown in the human system. The study of embryonic endothelial cells generated from hESCs may recapitulate events seen in vascular network formation and increases the understanding of the molecular mechanisms of vascular development (Figure 1 ).
Human and mouse embryonic stem cells
Similar to mouse embryonic stem (mES) cells, hESCs are derived from the inner cell mass (ICM) of blastocysts or morula stage embryos. 1, 18, 19 After removal from the ICM and maintenance in culture, hESCs acquire an immortal characteristic, that is, hESCs can grow indefinitely. They are capable of prolonged self-renewal and differentiation into cells of all three germ layers in vivo and in vitro. Mouse ES cells have been established and studied for more than 20 years. [20] [21] [22] [23] There is a substantial overlap between human and mouse ES cells in the expression of key transcription factors, including Oct3/4, Nanog and Sox2, which maintain pluripotency and self-renewal. However, some fundamental differences were demonstrated between human and mouse ES cells. For example, the population-doubling time of hESCs (B36 h) is significantly longer than that of mES cells (B12 h). Morphologically, hESCs form relatively flat and compact colonies. Undifferentiated hESCs express stage-specific embryonic antigen (SSEA)-3 and SSEA-4, but lack SSEA-1; whereas mES cells express SSEA-1 but lack SSEA-3 and SSEA-4. 1 Significantly, mES cells remain undifferentiated and proliferate in the presence of leukemia inhibitory factor (LIF), when MEF feeder cells are removed. 24 The requirement for MEF feeder cells to support undifferentiated hESCs is supplanted by the addition of FGF-2 and other factors, but not LIF, to the culture medium. 1, 25 Under serum-free conditions, BMP signaling synergizes with LIF for mES cell self-renewal. 26 In contrast to mES cells, suppression of BMP signaling by the antagonist noggin combined with FGF-2 sustains undifferentiation of hESCs. 27 The differences of human and mouse ES cells clearly demonstrate that hESCs not only have great potential for clinical application, but also provide a novel opportunity to add significant understanding to the field of early human development, which is hampered by the lack of experimental systems and cannot be accomplished by mouse models. ES cells can be triggered to undergo spontaneous differentiation by forming 3-dimensional embryoid bodies (EBs) containing many differentiated cell types. Although the EB is far less organized than an embryo, it can partially mimic the spatial organization of cells in an embryo. 23 Similar to mES cells, hESCs differentiate into EBs in vitro, and the differentiation process is somewhat directed by the culture environment. 28, 29 An enzymatic dissociation of hESC colonies into single cells leads to a significant decrease of ES cell propagation due to low efficiency of cell attachment, which is not typically associated with mES cells. 30 Therefore, most of the EB induction experiments from hESCs are performed as clumps from undifferentiated hESC colonies. Several cell types are characterized during hESC differentiation, including cardiac tissue, 31 neuronal tissue, 32 b-islet pancreatic cells, 33 hematopoietic cells 34 and endothelial cells. 35, 36 The hESC differentiation process follows a reproducible temporal pattern of development which, to some extent, resembles early human embryogenesis.
Development of hemangioblasts from hESCs
Zambidis et al. 37 studied cellular kinetics of hESC differentiation in serum-free clonogenic assays. When EB differentiation of hESCs were induced in 1% methylcellulose cultures containing fetal bovine serum (FBS), semiadherent mesodermal-hematoendothelial (MHE) cluster colonies emerged at days 6-9. 37 The MHE colonies contained adherent and nonadherent cells. Nonadherent cells of MHE colonies expressed CD45 and gave rise to hematopoietic colonies. Some adherent cells expressed endothelial markers, CD31, and were capable of Dil-Ac-LDL uptake, whereas other adherent cells expressed the mesenchymal marker vimentin. When the adherent cells from MHE colonies were isolated and cultured in endothelial medium (EGM-2), they were expanded to the cells with endothelial morphology, expressed the endothelial markers, CD31, VE-cad, vWF, and were capable of Dil-Ac-LDL uptake. 37 Because EB differentiation of this study was initiated from hESC clumps, it is unclear whether MHE colonies are generated from single hESCs. The relationship of MHE colonies and bipotential hemangioblast remains unknown. 
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The differentiation of embryonic endothelial cells from restricted angioblasts and bipotential hemangioblasts is dependent on their location during embryo development. 13, 14 The VEGF receptor VEGFR2 (or called Flk1 or KDR) is the earliest marker expressed by endothelial progenitor cells (EPCs) of avian and mouse embryos. VEGFR2+ cells in posterior mesoderm contain hemangioblasts, which are capable of differentiating into endothelial and hemopoietic cells, whereas VEGFR2+ angioblasts from anterior mesoderm give rise to only endothelial cells. 13 Embryonic endothelial cells can be derived from mouse, monkey and human ES cells. 36, 38, 39 In mES cell differentiation, the endothelial markers, VEGFR2, CD31 (or called PECAM-1), Tie-2, Tie-1 and VE-cadherin (VE-cad) are sequentially expressed in spontaneously differentiated cystic EBs. 40 ES-derived endothelial cells acquire these markers in a timedependent manner, which closely recapitulate endothelial differentiation in vivo during embryonic development. 40 A subpopulation of VEGFR2+ cells differentiated from mES cells contains hemangioblasts, which give rise to hematopoietic cells and endothelial cells. 41 Mouse embryos lacking VEGFR2 are embryonic lethal due to deficiency of hematopoietic and endothelial cells.
42
VEGFR2+ population from mouse ES cells contain cardiovascular progenitor cell subpopulations that give rise to cardiomyocyte, endothelial cells and vascular SMCs, [43] [44] [45] therefore suggesting the existence of a multipotential VEGFR2+ mesoderm precursor. The properties of cardiovascular progenitor cells from hESCs have not been characterized.
Bipotential hemangioblasts were also identified during hESC differentiation. Wang et al. 35 demonstrated that hematopoietic commitment occurred at around day 10 during EB differentiation of hES cells, because CD45+ cells and hematopoietic colonies were not observed before day 10 EBs in differentiation medium containing 20% FBS, BMP-4 and other cytokines. When CD31+/ VEGFR2+/VE-cad+ cells were isolated from day 10 EBs, they were capable of generating endothelial cells and hematopoietic cells in the culture of endothelial or hematopoietic medium, respectively. In the endothelial medium, the cells generated from CD31+/VEGFR2+/ VE-cad+ progenitor cells became phenotypically endothelial cells that expressed the endothelial markers, CD31, VE-cad, vWF and eNOS, and were capable of Dil-Ac-LDL uptake. When single CD31+/VEGFR2+/ VE-cad+ cells were cultured in the presence of both hematopoietic and endothelial growth factors, approximately 3.2% cells survived and formed endothelial or hematopoietic colonies, whereas a small portion of survived cells (B0.18% of single cells) gave rise to colonies with both endothelial and hematopoietic cells, suggesting that CD31+/VEGFR2+/VE-cad+ cells contain a subset of cells with hemangioblast properties. 35 It is unclear whether CD31+/VEGFR2+/VE-cad+ cells before day 10 EBs contain hemangioblast potential.
Kennedy et al. 46 recently demonstrated that in serumfree medium containing BMP-4, FGF-2 and VEGF, primitive erythroid progenitors were detected as early as 5 days EBs from differentiated hESCs. The kinetics of hematopoietic colony formation is different from previous studies, 35, 47 suggesting that different hESC differentiation conditions and growth factors result in different kinetics of hematopoiesis in vitro. When the VEGFR2+ cells from day 3 EBs were isolated and cultured in 1% methylcellulose containing hematopoietic and endothelial growth factors, a small portion of VEGFR2+ cells (B2.4%) formed blast-forming colonies (BL-CFCs). The BL-CFCs, which have both hematopoietic and endothelial differentiation potentials, were originally identified from mouse ES cells, and represent the equivalents of hemangioblasts in vitro. 41 The kinetics and frequency of BL-CFC formation from VEGFR2+ cells were slightly different depending on hESC lines. The BLCFCs have hematopoietic and endothelial differentiation potential. After culturing BL-CFCs for 6 days, nonadherent cells expressed hematopoietic genes and formed hematopoietic colonies, whereas adherent cells expressed the endothelial markers, VEGFR2, CD31, VEcad and P1HI2, and were capable of Dil-Ac-LDL uptake. 46 The differentiation of VEGFR2+ cells generated two subpopulations, CD31+/VEGFR2+ cells and CD31À/VEGFR2+ cells. All CD31+ cells also expressed CD34. Interestingly, CD31+/VEGFR2+ population, but not CD31À/VEGFR2+ population, give rise to the hematopoietic colonies, suggesting that CD31 is not only expressed in EPCs, but also in hematopoietic progenitor cells. 46 Recently, Lu et al. 48 used a two-step strategy to generate functional hemangioblasts from human ESCs. They generated early-stage EBs, and then plated individual cells of dissociated EBs in serum-free semisolid blast-colony growth medium to generate blast cells (hESBCs). The blast cells had characteristics of hemangioblasts giving rise to both multiple hematopoietic lineages and to endothelial cells. Approximately 0.5% of hESC developed to hES-BCs, and 60% of hES-BCs gave both hematopoietic (nonadherent) and endothelial (adherent) cells in the presence of hematopoietic and endothelial growth factors. When the blast cells were transplanted into a rat model with diabetes or into a mouse model with ischemia-reperfusion injury of the retina, they engrafted to the site of injury in the damaged vasculature, and appeared to participate in repair. Transplantation of the cells also reduced the mortality rate after myocardial infarction and restored blood flow in hind limb ischemia in mouse models. 48 Interestingly, VEGFR2, CD31 and CD34 were not expressed in hES-BCs, suggesting that hES-BCs have different properties from BL-CFCs in the study performed by Kennedy et al. 46 
Isolation of endothelial cells from hESCs
The hESC-derived endothelial cells were first identified and isolated in the Langer laboratory. 36 Levenberg et al.
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characterized the expression of endothelial-specific genes during EB differentiation in the hESC culture medium without additional growth factors. Although VEGFR2, Tie2 and CD133 were expressed in undifferentiated hESCs, the genes of CD31, CD34 and VE-cad were not expressed in undifferentiated hESCs. The levels of CD31, CD34 and VE-cad expression were increased during spontaneously EB formation, and reached a peak at day 13 to 15. The CD31+ cells (B2% of day 13 EB cells) were isolated from EBs by flow cytometry using anti-CD31 antibodies, and expanded in endothelial medium. The hESC-derived endothelial cells expressed endothelial markers, CD31, VE-cad, vWF and N-cadherin, and were
Generation of blood vessels from hESC H Bai et al capable of Dil-Ac-LDL uptake. The function of the embryonic endothelial cells derived from hESCs was assessed in severe combined immunodeficient (SCID) mice by subcutaneous implantation of the cells mixed in a synthetic biopolymer scaffold. The sections of implants examined after 14 days showed microvessels expressing human CD31 and CD34. 36 This study demonstrates that during EB induction, hESCs spontaneously differentiated in embryonic endothelial cells, which were isolated and maintained in vitro. However, the blood carrying function of the blood vessels generated by embryonic endothelial cells is not well characterized in vivo. The long-term durability and quality of embryonic endothelial cell-derived microvessels and their integration into host vasculature is not well defined. The phenotype of EPCs that give rise to hESC-derived endothelial cells needs further investigation.
To investigate endothelial cell development and understand the mechanisms of embryonic vessel formation in human early development, we intended to isolate EPCs from hESCs. Studies from adult circulating cells indicated that VEGFR2, CD133 and CD34 are expressed on endothelial and hematopoietic progenitor cells in several human tissues, including peripheral blood and bone marrow. [49] [50] [51] We chose CD34 as a possible marker to isolate hESC-derived EPCs, because VEGFR2 and CD133 are expressed in undifferentiated hESCs, whereas CD34 is not expressed (or minimally expressed) in undifferentiated hESCs. 36, 46, 52 In our study, CD34 + cell populations increased to approximately 10% at around day 12-15 upon EB differentiation. 36, 53 The CD34+ cells at day 10 EBs were negative for hematopoietic marker CD45, whereas the majority of CD34+ cells were also CD31+ cells. 53, 54 Similar results were obtained by other groups. 35, 36 After culture in endothelial cell medium, the isolated CD34 + progenitor cells gave rise to cells with endothelial morphology and expressed endothelial cell markers CD31, VE-cad and vWF. The hESC-derived endothelial cells were capable of Dil-Ac-LDL uptake, and formed vascular network in Matrigel. 53, 54 When CD34+ cells from hESCs were cultured in the presence of hematopoietic growth factors, they expressed CD45 and formed multilineage hematopoietic colonies on methylcellulose. 54 These results suggest that CD34+/CD31+ population contain hematopoietic and EPCs, although it is not clear that this occurs at a clonal level.
Whether there is a true hemangioblast population in CD34+/CD31+ cell fraction remains unknown. Highly efficient generation of CD34+ cells from hESCs can be achieved by simply changing the differentiation medium of the MEF feeder cells (Figure 2) . 54 In the presence of VEGF, FGF-2 and BMP-4, CD34+ progenitor cells can be derived from hESCs in a serum-free medium with similar efficiency as the serum-containing medium. 54 The blood vessel forming function of hESC-derived endothelial cells was demonstrated by implantation of green fluorescent protein (GFP)-expressing hESC-derived endothelial cells into SCID mice with the cranial windows. Through the cranial window, the behavior of GFP+ cells can be constantly monitored. After 11 days of implantation, the hESC-derived endothelial cells aggregated to form luminal structures. When rhodaminelabeled dextran was injected into the tail veins, the perfused vessels transported streaming red blood cells, suggesting the formation of functional engineered vessels that are successfully integrated into the recipient's vascular tree. 54 The generation of endothelial cells from hESCs not only provides a cell resource for potential clinical applications, it also provides an excellent alternative to study vasculogenesis and angiogenesis events in the human system. Using hESC-derived endothelial cells, Figure 2 Generation of hESC-derived endothelial cells in 2-dimensional (2D) culture. The GFP+ hESCs were differentiated in monolayer (2D) or EB (3D) cultures. The CD34+ cells were isolated by MACS columns, and cultured in the presence of angiogenic or hematopoietic growth factors for endothelial and hematopoietic differentiation. The hESC-derived endothelial cells (green) in a collagen gel were implanted into cranial windows in SCID mice. After 11 days, rhodamine-dextran was injected into the tail vein to highlight perfused vessels (red). SCID, severe combined immunodeficient.
Generation of blood vessels from hESC
H Bai et al the molecular mechanism of blood vessel formation during human embryonic development can be studied in vitro. We demonstrated a role of the SDF-1/CXCR4 signaling in human embryonic endothelial cell migration, branching and remodeling. 53 
HESC-derived smooth muscle cells
The majority of the studies of angiogenesis research focus on the regulation of endothelium. Endothelial cells alone cannot complete angiogenesis to form mature vasculature. Vascular SMCs play critical roles in structural and functional support of the vascular network by stabilizing nascent endothelial vessels during vascular development and blood vessel growth. 55 Endothelial cells and SMCs interact with each other to regulate not only new vessel growth, but also multiple vascular functions. In adult animals, SMCs regulate growth of blood vessels, vessel tone diameter, vascular permeability and blood flow distribution. 15 A study of mouse ES cells by Yamashita et al. 44 suggested that vascular progenitor cells (VPCs) can differentiated into either endothelial cells or SMCs dependent on VEGF or PDGF-BB, respectively. SMCs originate from multiple cell populations, including endothelial cells, neural crest cells, mesenchymal cells, bone marrow precursors or macrophages. For example, coronary vein SMCs are derived from the atrial myocardium, whereas coronary artery SMCs originate in the epicardial layer that also gives rise to perivascular fibroblasts and intermyocardial fibroblasts. 56 Our study found that co-implantation of hESC-derived endothelial cells and 10T1/2 cells (mouse embryonic fibroblasts) facilitated blood vessel formation in vivo. 54 However, it is unclear whether 10T1/2 cells directly interact with hESC-derived endothelial cells or secret soluble factors that enhance the hESC-derived endothelial cell vascular network. Recently, SMCs were characterized during hESC differentiation. 57 Retinoic acid has been used to induce mouse ES cells into SMCs. 58 When the hESCs were cultured in differentiation medium containing all-trans retinoid acid (atRA), more than 93% of the cells expressed SMC-markers, SM-MHC and SM a-actin, and were capable of contraction. 
Potentials and challenges in hESC therapy
The successful derivation of hES cells from blastocysts in 1998 by Thomson et al. 1 provides potential cell sources for cell-based therapies for many human diseases and injury. However, there are scientific obstacles that need to be overcome before clinical applications, such as animal product contamination, tumorigenicity, immunocompatibility, isolation of desired cell types and availability of suitable animal models to test cell function. For example, ES cells are pluripotent cells with self-renewal capability. When hESCs are injected subcutaneously, intramuscularly or into the testis, they form teratocarcinoma-like tumors in adult mice. 1, 18, 59 These tumors contain differentiated cells derived from all three germ layers. Therefore, any ES cell-based therapy has the risk of tumor formation from undifferentiated ES cells. Studies of mouse ES cells indicated that differentiated ES cells are less likely to generate teratomas after transplantation. [60] [61] [62] It is an important step to minimize the probability of teratomas by using highly differentiated ES cells. Highly differentiated cells often have low proliferation potential. Isolation of progenitors from differentiated hESCs may provide cells with potential of proliferation and differentiation. It is a great challenge to identify, characterize and isolate progenitor populations that will not form tumors, and is capable of proliferation and continually producing newly differentiating cells in vivo. When hESC-endothelial cells from CD34+ progenitor cells are implanted in SCID mice under the cranial windows, stable blood conduits form for more than 150 days without teratomas, 54 suggesting that hESC-derived endothelial cells are safe for potential clinical applications. Whether or not there is the long-term tumorigenicity needs to be further investigated.
Unlike mouse ES cells, in which a single cell is able to form an EB in methylcellulose cultures, 63 the formation of EBs from hESCs is inefficient and usually requires an entire colony of hESCs. Dispersed single hESCs aggregate inefficiently to form EBs, and a large number of dispersed cells undergo cell death during EB formation. 18 Due to spontaneous differentiation in EBs, differentiated hESCs contain heterogeneous multiple cell types simultaneously. Therefore, one of the major challenges in stem cell research is to obtain sufficient and desired cell types for clinical applications. Selecting progenitor cells rather than mature cell type from differentiated hESCs may be advantageous for in vitro expansion and in vivo function. Studies of endothelial cells from hESCs demonstrate that isolation of CD34+ EPCs is a suitable approach to generate endothelial cells.
The hESCs can be genetically manipulated. We and others have used lentiviral vectors to expressed transgenes. 54, 64, 65 After implanting GFP-marked endothelial cells, we are able to observe readily hESC-derived cells for at least 150 days. 54 Such procedures of genetic manipulation in hESCs could be used to correct genetic mutation in clinical gene therapy, to direct differentiation to a specific cell type, to reduce graft rejections by the modification of immune responses, or to trace hESCderived cells in vivo after transplantation.
